Manogepix (APX001A) Displays Potent In Vitro Activity against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs-Reference-Cited by-同舟云学术

Manogepix (APX001A) Displays Potent In Vitro Activity against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs

Published:2020-06-23 Issue:7 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Arendrup Maiken Cavling¹²³^ORCID,Jørgensen Karin Meinike¹

Affiliation:

1. Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark

2. Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark

3. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Abstract

Manogepix (APX001A) is the active moiety of the novel drug candidate fosmanogepix (APX001). We previously reported the broad-spectrum activity of manogepix but also observed a correlation between increased manogepix and fluconazole MICs. Here, we extended this study and included isolates with acquired fluconazole resistance. Isolates ( n = 835) were identified using CHROMagar, matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS), and, when needed, internal transcribed spacer (ITS) sequencing.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00429-20

Reference15 articles.

1. In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model

2. In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris

3. In VitroActivity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds

4. In VitroActivity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods

5. The Investigational Agent E1210 Is Effective in Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida albicans

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017–2022);Antimicrobial Agents and Chemotherapy;2024-01-11

2. The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo;Medical Mycology;2023-11

3. Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician;Infection and Drug Resistance;2023-02

4. Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020);Antimicrobial Agents and Chemotherapy;2022-11-15

5. Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents;Journal of Fungi;2022-08-16